SOURCE: Twidwell J, et al. Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: A randomized, prospective, placebo-controlled pilot study. Int J Impot Res 2016;28:41-45.
Peyronie’s disease is characterized by scarring of the tunica albuginea, which may result in angulation and/or pain when the penis is erect. While mild Peyronie’s disease is largely inconsequential, unless the sufferer has cosmetic concerns about the appearance of the erect penis, moderate to severe Peyronie’s disease may produce sufficient penile angulation as to make successful intercourse difficult or impossible.
Surgical intervention to modify the culprit scar lesion from the tunica is often successful, but many patients prefer less invasive interventions. Tools that have had some success with scar dissolution, such as intralesional verapamil, have not proven consistently effective in clinical trials.
H-100 oil is a combination of nicardipine and superoxide dismutase dissolved in emu oil, which is reportedly a good agent for enhancing transdermal absorption. Nicardipine blocks collagen production, and superoxide dismutase reduces inflammation through scavenging of free radicals.
Study subjects (n = 24) were randomized to H-100 or placebo. Both agents were applied twice daily to the penile shaft. At the 6-month endpoint of the trial, men who applied H-100 demonstrated significant improvements in penile curvature and reductions in erection pain. Treatment was well tolerated, with only one patient discontinuing due to a penile rash. H-100 is a promising agent for a vexing disorder that otherwise often requires surgical intervention.
H-100 is a promising agent for a vexing disorder that otherwise often requires surgical intervention.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content